Latest news
Synaffix Announces License Agreement worth up to $125 million with Leading Chinese ADC Developer, Shanghai Miracogen
AMSTERDAM, NETHERLANDS – April 10, 2019 – Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered...
Synaffix ADC Technology Enters the Clinic as Collaboration with ADC Therapeutics Advances
Lausanne, Switzerland, January 16, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I...
Synaffix Announces License Agreement with Mersana Therapeutics for the Use of its GlycoConnect™ Site-Specific ADC Technology
AMSTERDAM, NETHERLANDS – January 4, 2019 – Synaffix B.V. announced today it has entered into a license agreement with Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates...
BioGeneration Ventures’ portfolio company Staten Biotechnology announces collaboration with Novo Nordisk
BioGeneration Ventures (BGV) is pleased to announce that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement. Under the collaboration agreement, Staten will continue to develop its lead...
Next events
Swiss Biotech Day Basel – May 7
Daniela and Arnoud will attend the Swiss Biotech day. http://swissbiotechday.ch/home/
BioEquity 2019 Barcelona – May 20/21
Oskar will attend BioEquity 2019.
InvestEurope Forum Geneva – March 27/28
Edward will attend InvestEurope Forum Geneva.
Latest investments
